CIC
RPRX icon

Cornercap Investment Counsel’s Royalty Pharma RPRX Stock Holding History

Cornercap Investment Counsel’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-67,314
Closed -$2.04M – 682
2024
Q1 		$2.04M Buy
67,314
+382
+0.6% +$11.3K 0.31% 88
2023
Q4 		$1.88M Buy
66,932
+34,483
+106% +$948K 0.31% 91
2023
Q3 		$881K Buy
32,449
+6,175
+24% +$183K 0.16% 269
2023
Q2 		$808K Buy
26,274
+2,095
+9% +$71K 0.14% 318
2023
Q1 		$871K Buy
+24,179
New +$897K 0.15% 295

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Cornercap Investment Counsel's RPRX Position: Q2 2024 in Review

Cornercap Investment Counsel sold out of Royalty Pharma (RPRX) in Q2 2024, closing a stake of 67,314 shares — an estimated $2.04M sold.

Cornercap Investment Counsel first reported a position in RPRX in Q1 2023 and held it in 5 quarters. The position peaked at $2.04M in Q1 2024. 378 funds tracked by Wall St. Rank hold RPRX as of Q2 2024.

  • Cornercap Investment Counsel reported no remaining Royalty Pharma position as of Q2 2024 after selling out during the quarter.
  • Cornercap Investment Counsel sold 67,314 Royalty Pharma shares in Q2 2024, an estimated $2.04M.
  • Cornercap Investment Counsel first reported a position in Royalty Pharma in Q1 2023 and held it in 5 quarters.
  • Cornercap Investment Counsel's Royalty Pharma position peaked at $2.04M in Q1 2024.
  • 378 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2024.

Based on Cornercap Investment Counsel's 13F filing for Q2 2024, filed 8 Aug 2024.